Research Article| Volume 33, SUPPLEMENT 4, S35-S39, May 1997

Economic evaluation of cancer treatment strategies

      This paper is only available as a PDF. To read, Please Download here.
      Economic constraints are a reality in the European healthcare environment. Because it is impossible to adopt all potentially effective treatments without destabilising national welfare systems, the costs of different treatments have been considered when making decisions in hospitals and healthcare administrations. However, this has often been done implicitly, intuitively, or with suboptimal information. Today, economic evaluations are attracting increasing attention. Their aim is to consider the overall picture of costs and effectiveness associated with different treatments. The essential parts of an economic evaluation are an estimate of the additional costs incurred by one treatment over another and the formal comparison of these additional costs with the corresponding gain in effectiveness. Information on effectiveness should preferably come from large, prospective, randomised trials with sufficient external validity. Cost information is usually retrieved from various secondary data sources. A cost equals the amount of a resource used, multiplied by its unit price. Ideally, key data on resource use should be collected from the clinical trials providing effectiveness data. This approach requires close collaboration among clinicians, statisticians, and health economists in all phases of the trial process, including the design of the protocol. When economic evaluations result from a multidisciplinary approach and are systematically integrated into the whole clinical research process for all important new treatments, they become a powerful tool. They may assist decision makers on all levels to allocate scarce healthcare resources in a rational and optimal way, thereby allowing optimal gains in life expectancy and quality of life within budgetary limits.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kaplan RM
        Utility assessment for estimating quality-adjusted life years.
        in: Sloan FA Valuing Health Care. Cambridge University Press, Brussels1995: 15-30
        • Bennett KJ
        • Torrance GW
        Measuring health state preferences and utilities: rating scale, time trade-off and standard gamble techniques.
        in: Spilker B Quality of Life and Pharmacoeconomics in Clinical Trials. Lippincott-Raven, Cambridge1996: 253-266
        • Williams C
        • Coyle D
        • Gray A
        • et al.
        European School of Oncology Advisory Report to the Commission of the European Communities for the Europe Against Cancer programme cost-effectiveness in cancer care.
        Eur J Cancer. 1995; 31A: 1410-1424
      1. (Draft version)
        • Division of Drug Marketing, Advertising and Communications, U.S. Food and Drug Administration
        Principles for the Review of Pharmacoeconomic Promotion.
        in: Presented at Drug Information Association annual meeting, Orlando, Florida1995
        • Van Hout BA
        • My AL
        • Gordon GS
        • Rutten FFH
        Costs, effects and C/E ratios alongside a clinical trial.
        Health Econ. 1994; 3: 309-319
        • Weinstein MC
        From cost-effectiveness ratios to resource allocation: where to draw the line?.
        in: Sloan FA Valuing Health Care. Cambridge University Press, Philadelphia1995: 77-98
        • Drummond MF
        • Stoddard GL
        • Torrance GW
        Methods for the Economic Evaluation of Health Care Programmes.
        Oxford University Press, Cambridge1989
        • Commonwealth Department of Health, Housing, and Community Services
        Guidelines for the Pharmaceutical Industry Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Australian Government Publishing Service, Oxford1992
        • Canadian Coordinating Office for Health Technology Assessment
        Guidelines for Economic Evaluation of Pharmaceuticals. Canadian Coordinating Office for Health Technology Assessment, Canberra1994
        • Ministry of Health of Ontario
        Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Ministry of Health, Ottawa1994
        • Clemens K
        • Townsend R
        • Luscombe F
        • et al.
        Methodological and conduct principles for pharmacoeconomic research (PhRMA Pharmacoeconomics Guidelines).
        PharmacoEconomics. 1995; 8: 169-174
        • Task Force on Principles for Economic Analysis of Health Care Technology
        Economic Analysis of Health Care Technology: a report on principles. Position paper.
        Ann Intern Med. 1995; 122: 61-70
        • Drummond MF
        • Jefferson TO
        • the BMJ Economic Evaluation Working Party
        Guidelines for authors and peer reviewers of economic submissions to the BMJ.
        Br Med J. 1996; 313: 275-283
      2. Gold R Siegel JE Russell LB Weinstein MC Cost-effectiveness in Health and Medicine. Oxford University Press, Toronto1996